Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model

Toshi Murakami, Nagio Takigawa, Takashi Ninomiya, Nobuaki Ochi, Masaaki Yasugi, Yoshihiro Honda, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: STAT3 plays a vital role in inducing and maintaining a pro-carcinogenic inflammatory microenvironment and is reported to be a critical mediator of the oncogenic effects of EGFR mutations. STAT3 activation is mediated through JAK family kinases. We investigated the effect of the JAK1/2 inhibitor AZD1480 on lung tumors induced by an activating EGFR mutation. Materials and methods: Three EGFR tyrosine kinase inhibitor-resistant cell lines (RPC-9, PC-9/Van-R and PC-9/ER3) established from PC-9 harboring an EGFR exon19 deletion mutation were used. Growth inhibition was measured using an MTT assay. Effects of AZD1480 were also evaluated in the xenograft model and in the EGFR transgenic mice model. Protein expressions were assessed by immunoblotting and immunohistochemistry. Group differences were compared using Student's t-test. To evaluate the efficacy of AZD1480 on survival, AZD1480 or vehicle was administered orally from 7 weeks of age of the transgenic mice. Overall survival curves were calculated using the Kaplan-Meier method. Results: The sensitivities of resistant and parent cells to AZD1480 were similar in vitro. AZD1480 (30 or 50. mg/kg/day, per os) reduced angiogenesis and revealed significant tumor regression in a mouse xenograft model. Subsequently, the transgenic mice were treated with AZD1480 (30. mg/kg/day) or vehicle alone. The numbers of lung tumors (long axis exceeding 1. mm) in the AZD1480-treated group and control group were 0.37. ±. 0.18 and 2.25. ±. 0.53 (p

Original languageEnglish
Pages (from-to)30-36
Number of pages7
JournalLung Cancer
Volume83
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Transgenic Mice
Heterografts
Janus Kinases
Neoplasms
Lung
Mutation
Survival
AZD 1480
Sequence Deletion
Immunoblotting
Protein-Tyrosine Kinases
Immunohistochemistry
Students
Cell Line
Control Groups
Growth
Proteins

Keywords

  • EGFR
  • JAK2
  • Lung cancer
  • Oncogene addiction
  • STAT3
  • Transgenic mice

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. / Murakami, Toshi; Takigawa, Nagio; Ninomiya, Takashi; Ochi, Nobuaki; Yasugi, Masaaki; Honda, Yoshihiro; Kubo, Toshio; Ichihara, Eiki; Hotta, Katsuyuki; Tanimoto, Mitsune; Kiura, Katsuyuki.

In: Lung Cancer, Vol. 83, No. 1, 01.2014, p. 30-36.

Research output: Contribution to journalArticle

Murakami, Toshi ; Takigawa, Nagio ; Ninomiya, Takashi ; Ochi, Nobuaki ; Yasugi, Masaaki ; Honda, Yoshihiro ; Kubo, Toshio ; Ichihara, Eiki ; Hotta, Katsuyuki ; Tanimoto, Mitsune ; Kiura, Katsuyuki. / Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. In: Lung Cancer. 2014 ; Vol. 83, No. 1. pp. 30-36.
@article{b38ac21765e84658ae9af46a04b5de5f,
title = "Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model",
abstract = "Objective: STAT3 plays a vital role in inducing and maintaining a pro-carcinogenic inflammatory microenvironment and is reported to be a critical mediator of the oncogenic effects of EGFR mutations. STAT3 activation is mediated through JAK family kinases. We investigated the effect of the JAK1/2 inhibitor AZD1480 on lung tumors induced by an activating EGFR mutation. Materials and methods: Three EGFR tyrosine kinase inhibitor-resistant cell lines (RPC-9, PC-9/Van-R and PC-9/ER3) established from PC-9 harboring an EGFR exon19 deletion mutation were used. Growth inhibition was measured using an MTT assay. Effects of AZD1480 were also evaluated in the xenograft model and in the EGFR transgenic mice model. Protein expressions were assessed by immunoblotting and immunohistochemistry. Group differences were compared using Student's t-test. To evaluate the efficacy of AZD1480 on survival, AZD1480 or vehicle was administered orally from 7 weeks of age of the transgenic mice. Overall survival curves were calculated using the Kaplan-Meier method. Results: The sensitivities of resistant and parent cells to AZD1480 were similar in vitro. AZD1480 (30 or 50. mg/kg/day, per os) reduced angiogenesis and revealed significant tumor regression in a mouse xenograft model. Subsequently, the transgenic mice were treated with AZD1480 (30. mg/kg/day) or vehicle alone. The numbers of lung tumors (long axis exceeding 1. mm) in the AZD1480-treated group and control group were 0.37. ±. 0.18 and 2.25. ±. 0.53 (p",
keywords = "EGFR, JAK2, Lung cancer, Oncogene addiction, STAT3, Transgenic mice",
author = "Toshi Murakami and Nagio Takigawa and Takashi Ninomiya and Nobuaki Ochi and Masaaki Yasugi and Yoshihiro Honda and Toshio Kubo and Eiki Ichihara and Katsuyuki Hotta and Mitsune Tanimoto and Katsuyuki Kiura",
year = "2014",
month = "1",
doi = "10.1016/j.lungcan.2013.10.011",
language = "English",
volume = "83",
pages = "30--36",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model

AU - Murakami, Toshi

AU - Takigawa, Nagio

AU - Ninomiya, Takashi

AU - Ochi, Nobuaki

AU - Yasugi, Masaaki

AU - Honda, Yoshihiro

AU - Kubo, Toshio

AU - Ichihara, Eiki

AU - Hotta, Katsuyuki

AU - Tanimoto, Mitsune

AU - Kiura, Katsuyuki

PY - 2014/1

Y1 - 2014/1

N2 - Objective: STAT3 plays a vital role in inducing and maintaining a pro-carcinogenic inflammatory microenvironment and is reported to be a critical mediator of the oncogenic effects of EGFR mutations. STAT3 activation is mediated through JAK family kinases. We investigated the effect of the JAK1/2 inhibitor AZD1480 on lung tumors induced by an activating EGFR mutation. Materials and methods: Three EGFR tyrosine kinase inhibitor-resistant cell lines (RPC-9, PC-9/Van-R and PC-9/ER3) established from PC-9 harboring an EGFR exon19 deletion mutation were used. Growth inhibition was measured using an MTT assay. Effects of AZD1480 were also evaluated in the xenograft model and in the EGFR transgenic mice model. Protein expressions were assessed by immunoblotting and immunohistochemistry. Group differences were compared using Student's t-test. To evaluate the efficacy of AZD1480 on survival, AZD1480 or vehicle was administered orally from 7 weeks of age of the transgenic mice. Overall survival curves were calculated using the Kaplan-Meier method. Results: The sensitivities of resistant and parent cells to AZD1480 were similar in vitro. AZD1480 (30 or 50. mg/kg/day, per os) reduced angiogenesis and revealed significant tumor regression in a mouse xenograft model. Subsequently, the transgenic mice were treated with AZD1480 (30. mg/kg/day) or vehicle alone. The numbers of lung tumors (long axis exceeding 1. mm) in the AZD1480-treated group and control group were 0.37. ±. 0.18 and 2.25. ±. 0.53 (p

AB - Objective: STAT3 plays a vital role in inducing and maintaining a pro-carcinogenic inflammatory microenvironment and is reported to be a critical mediator of the oncogenic effects of EGFR mutations. STAT3 activation is mediated through JAK family kinases. We investigated the effect of the JAK1/2 inhibitor AZD1480 on lung tumors induced by an activating EGFR mutation. Materials and methods: Three EGFR tyrosine kinase inhibitor-resistant cell lines (RPC-9, PC-9/Van-R and PC-9/ER3) established from PC-9 harboring an EGFR exon19 deletion mutation were used. Growth inhibition was measured using an MTT assay. Effects of AZD1480 were also evaluated in the xenograft model and in the EGFR transgenic mice model. Protein expressions were assessed by immunoblotting and immunohistochemistry. Group differences were compared using Student's t-test. To evaluate the efficacy of AZD1480 on survival, AZD1480 or vehicle was administered orally from 7 weeks of age of the transgenic mice. Overall survival curves were calculated using the Kaplan-Meier method. Results: The sensitivities of resistant and parent cells to AZD1480 were similar in vitro. AZD1480 (30 or 50. mg/kg/day, per os) reduced angiogenesis and revealed significant tumor regression in a mouse xenograft model. Subsequently, the transgenic mice were treated with AZD1480 (30. mg/kg/day) or vehicle alone. The numbers of lung tumors (long axis exceeding 1. mm) in the AZD1480-treated group and control group were 0.37. ±. 0.18 and 2.25. ±. 0.53 (p

KW - EGFR

KW - JAK2

KW - Lung cancer

KW - Oncogene addiction

KW - STAT3

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=84891747089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891747089&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.10.011

DO - 10.1016/j.lungcan.2013.10.011

M3 - Article

VL - 83

SP - 30

EP - 36

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -